All In Biotech

Drug Trial Radar · NCT05106179

The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma

The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma: a Prospective Cohort Study

Last checked: Nov 20, 2026Latest source record: Nov 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Dec 2021

Primary completion

Dec 2022

Study completion Dec 2023

Sponsor

Lead sponsor
Center for Vascular Pathology, MoscowAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Spinal hemangioma is one of the most common benign vertebral tumours. Being mostly asymptomatic, it is still associated with a pain syndrome especially if encroaches into the neural canal. This study is organised to evaluate the efficacy and safety of β-blockers drugs in adults with spinal hemangioma.

Conditions

  • Spinal Tumor
  • Spinal Hemangioma
  • Beta Blocker Toxicity

Interventions

  • Atenolol PillDrug

    Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.

  • Propranolol PillDrug

    Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reducing tumor growthTime frame: 3 months
  2. Reducing tumorTime frame: 6 months
  3. Life-qualityTime frame: 3 months and 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Vascular Anomalies Center (VAC) "Hemangioma"

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.